Precise estimation of Creatinine (CRE) is an indispensable analysis used in the clinical settings for early stage detection of kidney dysfunction. In the present work, we described the non-enzymatic detection of serum CRE using ellipsoidal nanostructured Fe2O3 integrated polyaniline (PANI) nanocomposite sensor platform. Hydrothermally derived Fe2O3 was distributed on the PANI matrices to form supramolecular nanocomposite via simple oxidative polymerization method. The Fe2O3 coordinated PANI composite showed better complex formation ability towards CRE with improved active surface area and charge transfer efficiency compared to pristine Fe2O3 and PANI. Further, the scan rate analysis confirmed the quasi-reversible diffusion controlled electrochemical kinetics of the reaction. The differential pulse voltammetry (DPV) outcomes evidenced the higher sensitivity with wide linear detection range (1 μM -13 mM), lower detection limit (144 nM) and enhanced selectivity. The blood serum sample analysis of pre and post dialysis patients ensured that our prepared Fe2O3/PANI-1 composite exhibited better recovery percentage (91.9%) and Bland-Altman plot showed statistical bias is laid within the 95% confidence interval (CI). The glomerular filtration rate (GFR) index calculated from Modification of Diet in Renal Disease (MDRD) equation from our experimental results and the values have been validated with the commercial Jafee's method. The overall analysis confirmed that the prepared Fe2O3/PANI nanocomposite modified electrode has improved sensitivity and selectivity towards target molecule without the aid of any bio receptors and binders in real time CRE quantification with better accuracy.

中文翻译：

---

Fe2O3/聚苯胺超分子纳米复合材料：一种用于血清肌酐定量测定的无受体传感器平台

肌酐 (CRE) 的精确估计是临床环境中必不可少的分析，用于早期检测肾功能障碍。在目前的工作中，我们描述了使用椭圆形纳米结构 Fe2O3 集成聚苯胺 (PANI) 纳米复合传感器平台对血清 CRE 的非酶检测。水热衍生的 Fe2O3 分布在 PANI 基质上，通过简单的氧化聚合方法形成超分子纳米复合材料。与原始的 Fe2O3 和 PANI 相比，Fe2O3 配位的 PANI 复合材料对 CRE 显示出更好的复合物形成能力，具有更高的活性表面积和电荷转移效率。此外，扫描速率分析证实了反应的准可逆扩散控制电化学动力学。差分脉冲伏安法 (DPV) 结果证明具有较高的灵敏度和较宽的线性检测范围 (1 μM -13 mM)、较低的检测限 (144 nM) 和增强的选择性。透析前后患者的血清样本分析确保我们制备的 Fe2O3/PANI-1 复合物表现出更好的恢复百分比 (91.9%)，并且 Bland-Altman 图显示统计偏差位于 95% 置信区间 (CI) 内。肾小球滤过率 (GFR) 指数从我们的实验结果中的肾脏疾病饮食修正 (MDRD) 方程计算得出，并且这些值已经用商业 Jafee 的方法进行了验证。